Lv51
1190 积分 2023-04-17 加入
Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China
6小时前
待确认
Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer
4天前
已完结
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study
5天前
已完结
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study
5天前
已完结
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
10天前
已完结
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
21天前
已完结
Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: a single-center experience
23天前
已完结
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
24天前
已完结
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)
24天前
已完结
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
24天前
已完结
皖公网安备34019202002308
